Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib

NCT04053322 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT04053322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04053322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 26, 2019
Completion date
August 31, 2027
Enrollment
172 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

a germline or somatic brca mutation, or a deleterious alteration of other genes involved in homologous recombination repair (hrr) or in msi status, er-positive and her2-negative metastatic or locally advanced breast cancer